Abstract：
OBJECTIVE: Hormonal treatment is the preferred initial systemic therapy for patients with advanced or recurrent G1 or G2 endometrial cancer (EC) in terms of efficacy, toxicity, and economy. Few reports are available on the topic and we, therefore, conducted a retrospective study.
METHODS: Patients with EC who received high-dose medroxyprogesterone (MPA) at our Hospital between January 2010 and December 2022 were reviewed. Patients who were treated for fertility preservation or had a history of systemic chemotherapy other than adjuvant therapy were excluded.
RESULTS: Sixteen patients who were eligible for study inclusion had recurrent G1 or G2 EC. Their median age was 65 years (range=51-82 years), median body mass index was 22.6 kg/m2 (range=15.3-43.2 kg/m2), and all patients had an ECOG Performance Status of 0. All patients received 200 mg/day of MPA, and eight patients concomitantly received 100 mg/day of aspirin. None of the patients experienced severe adverse events. One patient had grade 2 deep vein thrombosis. Two patients discontinued MPA treatment because of adverse events. The response rate was 44% [95% confidence interval (CI)=20-68%] and median progression-free survival (PFS) was 6.9 months (95% CI=7.5-26 months). Four of 16 patients had PFS longer than 12 months, all of whom had positive tissue estrogen receptor (ER) and progesterone receptor (PR), and PFS at 2 years was 35% (95% CI=10.2-59.8%).
CONCLUSIONS: Hormone therapy is effective long-term in ER- and PR-positive EC and can be recommended as initial systemic therapy. Toxicity is mild and manageable.
METHODS: Patients with EC who received high-dose medroxyprogesterone (MPA) at our Hospital between January 2010 and December 2022 were reviewed. Patients who were treated for fertility preservation or had a history of systemic chemotherapy other than adjuvant therapy were excluded.
RESULTS: Sixteen patients who were eligible for study inclusion had recurrent G1 or G2 EC. Their median age was 65 years (range=51-82 years), median body mass index was 22.6 kg/m2 (range=15.3-43.2 kg/m2), and all patients had an ECOG Performance Status of 0. All patients received 200 mg/day of MPA, and eight patients concomitantly received 100 mg/day of aspirin. None of the patients experienced severe adverse events. One patient had grade 2 deep vein thrombosis. Two patients discontinued MPA treatment because of adverse events. The response rate was 44% [95% confidence interval (CI)=20-68%] and median progression-free survival (PFS) was 6.9 months (95% CI=7.5-26 months). Four of 16 patients had PFS longer than 12 months, all of whom had positive tissue estrogen receptor (ER) and progesterone receptor (PR), and PFS at 2 years was 35% (95% CI=10.2-59.8%).
CONCLUSIONS: Hormone therapy is effective long-term in ER- and PR-positive EC and can be recommended as initial systemic therapy. Toxicity is mild and manageable.
摘要：
目的：就疗效而言，激素治疗是晚期或复发的G1或G2子宫内膜癌（EC）患者的首选初始全身治疗，毒性,和经济。关于这个主题的报告很少，我们，因此,进行了一项回顾性研究。
方法：回顾了2010年1月至2022年12月在我们医院接受高剂量甲羟孕酮（MPA）治疗的EC患者。排除接受生育力保留治疗或有除辅助治疗外的全身化疗史的患者。
结果：16例符合纳入研究条件的患者有复发的G1期或G2期EC。他们的中位年龄为65岁（范围=51-82岁），中位体重指数为22.6kg/m2（范围=15.3-43.2kg/m2），所有患者的ECOG表现状态均为0。所有患者接受200毫克/天的MPA，8例患者同时接受100mg/天的阿司匹林。没有患者经历严重的不良事件。一名患者患有2级深静脉血栓。两名患者因不良事件而停止MPA治疗。缓解率为44％[95％置信区间（CI）=20-68％]，中位无进展生存期（PFS）为6.9个月（95％CI=7.5-26个月）。16例患者中有4例PFS超过12个月，所有这些人都有阳性的组织雌激素受体（ER）和孕激素受体（PR），2年PFS为35%（95%CI=10.2-59.8%）。
结论：激素治疗对ER和PR阳性的EC长期有效，可推荐作为初始全身治疗。毒性是温和和可控的。
方法：回顾了2010年1月至2022年12月在我们医院接受高剂量甲羟孕酮（MPA）治疗的EC患者。排除接受生育力保留治疗或有除辅助治疗外的全身化疗史的患者。
结果：16例符合纳入研究条件的患者有复发的G1期或G2期EC。他们的中位年龄为65岁（范围=51-82岁），中位体重指数为22.6kg/m2（范围=15.3-43.2kg/m2），所有患者的ECOG表现状态均为0。所有患者接受200毫克/天的MPA，8例患者同时接受100mg/天的阿司匹林。没有患者经历严重的不良事件。一名患者患有2级深静脉血栓。两名患者因不良事件而停止MPA治疗。缓解率为44％[95％置信区间（CI）=20-68％]，中位无进展生存期（PFS）为6.9个月（95％CI=7.5-26个月）。16例患者中有4例PFS超过12个月，所有这些人都有阳性的组织雌激素受体（ER）和孕激素受体（PR），2年PFS为35%（95%CI=10.2-59.8%）。
结论：激素治疗对ER和PR阳性的EC长期有效，可推荐作为初始全身治疗。毒性是温和和可控的。
